- Medicine Information and Evidence for Policy > Medicines Policy
- Medicine Access and Rational Use > Rational Use
(1998; 113 pages)
Andrews, P., “A Summary of the Efficacy of Praziquantel against Schistosomes in Animal Experiments and Notes on its Mode of Action,” Arzneimittel-Forschung/Drug Research 31: 539-541, 1981.
Andrews, Peter, et al., “Praziquantel,” Medicinal Research Reviews. 3(2):147-200, 1983.
Blankespoor, H.D., and R.L. Reimink, “The Control of Swimmer’s Itch in Michigan: Past, Present, and Future,” Michigan Academician 24:7-23, 1991.
Brown, P., “Deadly Worm May Be Turning Drug-Resistant,” New Scientist, November 12, 1994:4.
Cioli, D, et al., “Drug Resistance in Schistosomes,” Parasitology Today 9:162-166, 1993.
CFR (Code of Federal Regulations), No. 53,231 at page 48,532. December 1, 1988.
CFR, No. 55,015 at page 2233. January 23, 1990.
CFR, No. 58,026 at page 7864. February 10, 1993a.
CFR, No. 58,154 at page 42,852. August 12, 1993b.
CFR, No. 58,211 at page 58,561. November 3, 1993c.
Clark, W.G., D.C. Brater, and A.R. Johnson, eds., Goth’s Medical Pharmacology, 12th edition, St Louis: The C.V. Mosby Co., 1988.
Cook, Joseph, and Michael R. Reich, “Case 4-1996: Paralysis due to Schistosomiasis,” New England Journal of Medicine 334:1548-1549, 1996.
da Silva, L. C., H. Sette, Jr., C.H. Christo, A. Sáez-Alquezar, C.R.W. Carneiro, C.M. Lacet, N. Ohtsuki, and S. Raia, “Praziquantel in the Treatment of the Hepatosplenic Form of Schistosomiasis Mansoni,” Arzneimittel-Forschung/Drug Research 31(I)(3a):601-603, 1981.
Davis, A., “Available Chemotherapeutic Tools for the Control of Schistosomiasis,” Behring Institute Mitteilungen [Behring Institute Research Communications] 71:90-103, 1982.
Davis, Andrew, “Antischistosomal Drugs and Clinical Practice,” in P. Jordan, G. Webbe, and R. Sturrock, editors. Human Schistosomiasis. Cambridge: Cambridge University Press, 1993: 367-404.
Davis, A., and D.H. Wegner, “Multicenter Trials of Praziquantel in Human Schistosomiasis: Design and Techniques,” Bulletin of the World Health Organization 57(5): 767-771, 1979.
Davis, A., J.E. Biles, and A.M. Ulrich, “Initial Experiences with Praziquantel in the Treatment of Human Infections due to Schistosoma Haematobium,” Bulletin of the World Health Organization 57(5): 773-779, 1979.
Davis, A., J.E. Biles, A.M. Ulrich, and H. Dixon, “Tolerance and Efficacy of Praziquantel in Phase IIA and IIB Therapeutic Trials in Zambian Patients,” Arzneimittel-Forschung/Drug Research 31(3a): 568-574, 1981.
Dollery, Collin, ed., Therapeutic Drugs, Volume 2. London: Churchill Livingstone, 1991.
Fallon, P.G., and M.J. Doenhoff, “Drug-resistant Schistsomiasis: Resistance to Praziquantel and Oxamniquine induced in Schistosomiasis Mansoni in Mice is Drug Specific,” American Journal of Tropical Medicine and Hygiene 51:83-88, 1994.
Goth A., Medical Pharmacology: Principles and Concepts, 5th and 8th editions, St Louis: The C.V. Mosby Co., 1970 and 1976.
Groll, Erhard, “Praziquantel,” Advanced Pharmacology Chemotherapy 20:219-238, 1984.
Gryseels, B., “The Relevance of Schistosomiasis for Public Health,” Tropical Medicine and Parasitology 40:134-142, 1989.
Gryseels B, et al., “Field Trials of Praziquantel and Oxamniquine for the Treatment of S. Mansoni in Burundi,” Transactions of the Royal Society for Tropical Medicine and Hygiene 8: 641-644, 1987.
Gustafson, L.L., et al., Handbook of Drugs for Tropical Parasitic Infections. New York: Taylor and Francis, 1987.
Hunter, J.M., L. Rey, K.Y. Chu, E.O. Adekolu-John, and K.E. Mott, Parasitic Diseases in Water Resources Development: The Need for Intersectoral Negotiation. Geneva: World Health Organization, 1993.
Ishizaki, T., E. Kamo, and K. Boehme, “Double-blind Studies of Tolerance to Praziquantel in Japanese Patients with Schistosoma Japonicum Infections,” Bulletin of the World Health Organization 57(5): 787-791, 1979.
Jordan, P., G. Webbe, and R. Sturrock, eds., Human Schistosomiasis. Tucson, AZ: University of Arizona Press, 1993.
Katz, N., R.S. Rocha, and A. Chaves, “Preliminary Trials with Praziquantel in Human Infections Due to Schistosoma Mansoni,” Bulletin of the World Health Organization 57(5):781-785, 1979.
King, C.H., and A.A. Mahmoud, “Drugs Five Years Later: Praziquantel,” Annals of Internal Medicine 110(4):290-296, 1989.
Korte, R., Managing Specialized and Integrated Schistosomiasis Control Programmes in Four African Countries. A Workshop on Organization and Management of Schistosomiasis and Other Tropical Disease Control Programmes. (Workshop Material; v. No. 15), June, 1986.
Kumar, V., B. Gryseels, “Use of Praziquantel Against Schistosomiasis: A Review of Current Status,” International Journal of Antimicrobial Agents 4:313-320, 1994.
Leopold, G., W. Ungethum, E. Groll, Diekmann, H. Nowak, and D.H.G. Wegner, “Clinical Pharmacology in Normal Volunteers of Praziquantel, a New Drug against Schistosomes and Cestodes,” European Journal of Clinical Pharmacology 14: 281-291, 1978.
McMahon, J.E., “Observations on Praziquantel against Schistosomiasis Haematobium,” Arzneimittel-Forschung/Drug Research 31(I)(3a): 579-580, 1981.
Santos A.T., B.L. Blas, J.S. Noseños, G.P. Portillo, O.M. Ortega, M. Hayashi, and K. Boehme, “Preliminary Clinical Trials with Praziquantel in Schistosoma Japonicum Infections in the Philippines,” Bulletin of the World Health Organization 57(5):793-799, 1979.
Scrip, “Bayer’s African Launch of Praziquantel Will Adopt ‘New Approach’,” Scrip No. 581, April 13, 1981: 15.
Seubert, J., R. Pohlke, and F. Loebich, Experentia 33: 1036, 1977a.
Seubert, J., E. Merck, Inc., H. Thomas, and P. Andrews, “2-acyl-4-oxo-pyrazino-isoquinoline Derivatives and the Process for the Preparation Theoreof,” US Patent No. 4,001,411. Filed on 16 December 1974. Patent on 4 January 1977b.
Spilker, Bert, Multinational Pharmaceutical Companies: Principles and Practices. Second ed. New York: Raven Press, 1994.
Stelma, F.F. et al., “Efficacy and Side Effects of Praziquantel in an Epidemic Focus of S. Mansoni” American Journal of Tropical Medicine and Hygiene, forthcoming.
Utroska, J. A., M.G. Chen, H. Dixon, S. Yoon, M. Helling-Borda, H.V. Hogerzeil , and K.E. Mott, An Estimate of the Global Needs for Praziquantel Within Schistosomiasis Control Programmes. Geneva: World Health Organization, 1989.
Verg, E., P. Gottfried, and H. Schultheis, Meilensteine 125 Jahre Bayer, 1863-1988. Leverkusen, Germany: Bayer, A.G. August, 1988.
Webbe, G., C. James, G.S. Nelson, and R.F. Sturrock, “The Effect of Praziquantel on Schistosoma Haematobium, S. Japonicum and S. Mansoni in Primates,” Arzneimittel-Forschung/Drug Research 31(I)(3a): 542-554, 1981.
Wegner, D.H.G., “The Treatment of Human Schistosomiasis with Biltricide (Praziquantel, EMBAY 8440),” Bayer Publication. Germany: Bayer, Inc. 1979. (Paper 14 Joint Conference on Parasitic Disease, The United States of America-Japan Cooperative Medical Science Programme, New Orleans, 12-15 August 1979).
Wegner, D.H., “Trial Designs for Multicentre Clinical Studies of Investigational Phases I B to III with Praziquantel,” Arzneimittel-Forschung/Drug Research 31(3a): 566-567, 1981.
Wegner, D.H.G., “The Profile of the Trematodicidal Compound Praziquantel,” Arzneimittel-Forschung/Drug Research 34 (II), n.96:1132-1136, 1984.
World Health Organization, The Control of Schistosomiasis. Report of a WHO Expert Committee. Technical Report Series no. 728. Geneva: WHO, 1985.
World Health Organization, The Control of Schistosomiasis. Second Report of the WHO Expert Committee. Technical Report Series no. 830. Geneva: WHO, 1993.